APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: People with PD are at high risk of developing cognitive impairment and dementia. Cross‐sectional studies have identified candidate biomarkers associated with cognitive decline. However, longitudinal studies on this topic are rarer, and few have investigated the use of biomarker panels encompassing multiple modalities. The objective of this study was to find baseline predictors of cognitive decline in longitudinally followed, nondemented Parkinson's disease patients. Methods: We performed a prospective cohort study of 100 PD patients with a median disease duration of 6.4 years. All participants were nondemented at baseline. We examined 16 baseline biomarkers from clinical, genetic, biochemical, and MRI‐based imaging modalities for their association with longitudinal cognitive decline for up to 8 years. We investigated biomarkers individually, as well as in a multivariate linear mixed‐effects model encompassing multimodal biomarkers, with change in the Mattis Dementia Rating Scale‐2 over time as the primary outcome. Annual consensus process‐derived cognitive diagnosis was used for Cox proportional hazards modeling of risk for cognitive decline. Results: In multivariate analysis, the presence of the APOE E4 allele, thought disorder, and an Alzheimer's disease pattern of brain atrophy (spatial pattern of abnormality for recognition of early Alzheimer's disease index) best predicted cognitive decline, with APOE E4 genotype exerting the greatest effect. The presence of the APOE E4 allele was associated with a 3.5 times higher risk of worsening cognitive diagnosis over time (HR, 3.53; 95% CI, 1.52‐8.24; P < 0.05). The APOE genotype effect was not specific to any Mattis Dementia Rating Scale‐2 domain. Conclusions: Our results confirm the importance of Alzheimer's disease biomarkers as risk factors for cognitive decline in established Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Risk of dementia in Parkinson’s disease: A community-based, prospective study
Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., Nielsen, H., & Kragh–Sørensen, P. (2001) · Neurology · doi:10.1212/wnl.56.6.730 · Cited by 721
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Fan, Y., Batmanghelich, N., Clark, C. M., & Davatzikos, C. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.031 · Cited by 477
Self-citationApolipoprotein E and Cognitive Performance: A Meta-Analysis.
Small, B. J., Rosnick, C. B., Fratiglioni, L., & Bäckman, L. (2004) · Psychology and Aging · doi:10.1037/0882-7974.19.4.592 · Cited by 447
Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging
Davatzikos, C., Fan, Y., Wu, X., Shen, D., & Resnick, S. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.010 · Cited by 385
Self-citationAPOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies
Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.600 · Cited by 378
Self-citationDavatzikos, C., Xu, F., An, Y., Fan, Y., & Resnick, S. M. (2009) · Brain · doi:10.1093/brain/awp091 · Cited by 315
Self-citation
Cited by
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
APOE genotype regulates pathology and disease progression in synucleinopathy
Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., Haines, J. N., Dhavale, D. D., Miller, R., Choudhury, F. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3069 · Cited by 177
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid
Zhao, N., Attrebi, O. N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y. A., Meneses, A. D., Li, F., Shue, F., Zheng, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1809 · Cited by 156
Saeed, U., Mirza, S. S., MacIntosh, B. J., Herrmann, N., Keith, J., Ramirez, J., Nestor, S. M., Yu, Q., Knight, J., Swardfager, W., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.005 · Cited by 48
Metadata
- Authors
- Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., Weintraub, D., & Chen‐Plotkin, A. S.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2017-11-23
- Volume
- 33
- Issue
- 2
- Pages
- 289-297
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2770569755
- Cited by
- 50
- References
- 14
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.27204
- The paper
- Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., Weintraub, D., & Chen‐Plotkin, A. S. (2018). APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.27204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.